Elekta (OTCMKTS:EKTAY) Trading 0.2% Higher – Time to Buy?

Elekta AB (OTCMKTS:EKTAY)’s share price traded up 0.2% on Friday . The stock traded as high as $6.1085 and last traded at $6.1085. 2,000 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 2,934 shares. The stock had previously closed at $6.0940.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 16th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

Elekta Price Performance

The company has a debt-to-equity ratio of 0.66, a current ratio of 1.04 and a quick ratio of 0.82. The firm has a 50-day moving average of $5.43 and a 200 day moving average of $5.17. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 87.28 and a beta of 1.04.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings data on Wednesday, November 26th. The company reported $0.07 earnings per share for the quarter. Elekta had a net margin of 1.62% and a return on equity of 12.14%. The company had revenue of $427.85 million for the quarter, compared to analyst estimates of $436.91 million. As a group, sell-side analysts forecast that Elekta AB will post 0.36 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.